Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
Launched by SHER-E-BANGLA MEDICAL COLLEGE ยท
Trial Information
Current as of September 11, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well and how safely a medicine called extended-release paliperidone works for adults with schizophrenia in Bangladesh. Schizophrenia is a condition that affects how a person thinks, feels, and behaves. The study will look at whether this medicine helps improve symptoms like hallucinations or confused thinking, using a standard symptom rating scale. It will also check for any side effects and see if the medicine helps improve the overall quality of life for participants.
Adults of any gender with schizophrenia may be eligible to join this study. While specific age details seem unclear, the trial is open to a broad adult age range. Participants in the study will receive the paliperidone medicine and have their symptoms, side effects, and quality of life monitored over time. This study is not yet recruiting, so if you or a family member are interested, you may want to stay in touch with the study center for updates.
Gender
ALL
Eligibility criteria
About Sher E Bangla Medical College
Sher-e-Bangla Medical College is a prominent healthcare institution dedicated to advancing medical education, research, and clinical care in Bangladesh. As a clinical trial sponsor, the college plays a pivotal role in investigating innovative treatments and therapies, fostering collaboration among healthcare professionals, researchers, and regulatory bodies. With a commitment to ethical standards and patient safety, Sher-e-Bangla Medical College aims to contribute significantly to the scientific community and improve health outcomes through rigorous clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dr. M M Jalal Uddin Co-invetigator, MBBS,FCPS (Psychiatry), MPH
Study Director
National Institute of Neurosciences and Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported